Welcome to our dedicated page for Selectis Health SEC filings (Ticker: GBCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Selectis Health, Inc. (GBCS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Selectis Health’s healthcare facility portfolio, financing arrangements, and corporate governance decisions, complementing the company’s press releases.
For Selectis Health, Current Reports on Form 8-K are particularly important. Recent 8-K filings have disclosed material events such as definitive purchase and sale agreements for skilled nursing facilities in Georgia, related operations transfer agreements, and the terms of a Third Amended and Restated Allonge and Modification Agreement for senior secured promissory notes. Other 8-Ks describe appointments of new board members and changes in leadership roles, providing context on the company’s governance and oversight.
Investors can also review Selectis Health’s periodic reports, such as Forms 10-Q and 10-K, which include discussions of healthcare operations, facility performance, and revisions to previously issued financial statements, as referenced in the company’s communications. These filings may address topics like revenue from healthcare operations, operating expenses, and revisions related to accounting for healthcare revenue and intercompany transactions.
On Stock Titan, AI-powered summaries help explain the key points in lengthy filings, highlighting items such as transaction terms, maturity extensions for debt, warrant modifications, and board appointments. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports, when filed, can be used to track equity dealings by directors and officers. This page is intended as a centralized view of Selectis Health’s regulatory history, enabling users to quickly understand the substance of each filing without reading every page in full.
Selectis Health, Inc. reported that David Furstenberg resigned as a member of its Board of Directors and Audit Committee, effective immediately on March 30, 2026. The company expressed appreciation for his generous service and support, and the report was signed by CEO Adam Desmond.
Selectis Health, Inc. has filed a Schedule 14D-9 in response to a $5.05 per share cash tender offer from Black Pearl Equities, LLC to buy up to 100% of the Company’s common stock. As of March 9, 2026, 3,067,059 shares were issued and outstanding.
The Board has taken a neutral position and is not recommending whether stockholders should tender. The Board reviewed trading history, considered asset valuations (company estimates asset value ~$34,300,000, potential total assets up to $45,600,000, liabilities ~$18,700,000, and an estimated net value of $26,900,000), and noted ongoing negotiations with Purchaser concerning a possible higher offer. Insiders beneficially own 496,640 shares in the aggregate and hold 67,500 warrants exercisable at $2.25.
Selectis Health, Inc. reported that its Board of Directors approved the appointment of Richard Huebner, age 68, as a new director effective March 12, 2026. Huebner has served as senior managing partner and investment banker at GVC Capital LLC since 2001 and previously held senior roles at Fiserv Correspondent Services and Hanifen Imhoff entities, as well as legal and compliance positions at First Mid America, Inc.
He holds a bachelor’s degree from Hastings College in Nebraska (1979) and a Juris Doctor degree from the University of Nebraska (1982). As an outside director, Huebner will be eligible to participate in the company’s Outside Directors Compensation Plan and receive an annual cash stipend of $30,000, payable quarterly.
Black Pearl Equities, LLC is launching a fixed-price tender offer to purchase up to 100% of Selectis Health, Inc.'s common stock at $5.05 per share. The Offer seeks up to 3,067,059 shares (shares outstanding as of March 10, 2026) and is scheduled to expire on May 11, 2026 at 5:00 p.m.
The Offer is conditioned on at least 51% of outstanding shares on a fully diluted basis being validly tendered (the Minimum Tender Condition), a rights‑plan waiver and charter ownership limitation waiver, and reasonable access to customary due diligence materials. The Offeror states funding of approximately $15,500,000 from Milrose Capital, LLC and reserves rights to extend, increase, amend, or waive conditions.
Black Pearl Equities, LLC has launched a fixed-price tender offer to acquire up to 100% of Selectis Health, Inc. common stock at $5.05 per share. The Offer seeks up to 3,067,059 shares (the company’s shares outstanding as of March 10, 2026) and is conditioned on at least 51% of outstanding shares on a fully diluted basis being validly tendered. The Offer is scheduled to expire on May 11, 2026, is funded by Milrose Capital, LLC, and includes conditions requiring waivers of any rights plan and ownership limits before closing.
Selectis Health, Inc. entered into a definitive Purchase and Sale Agreement for two of its skilled nursing facilities in Georgia. Two wholly-owned property subsidiaries agreed to sell substantially all real and personal property related to the 101-bed Glen Eagle Healthcare and Rehab in Abbeville and the 100-bed Eastman Healthcare and Rehab in Eastman for a combined purchase price of $15,700,000, subject to customary prorations, holdbacks, and adjustments. Closing is contingent on completion of due diligence and other conditions, and may not occur.
At the same time, Selectis caused its operating subsidiaries to sign an Operations Transfer Agreement with new affiliated operators. If the sale is completed, this agreement will govern the transfer of the skilled nursing operations at both facilities to the new operators, with consummation of the operations transfer also contingent on closing of the property sale.
Black Pearl Equities, LLC plans an all-cash tender offer to acquire all outstanding shares of Selectis Health, Inc. at $4.00 per share. The offer is expected to proceed under a definitive acquisition agreement between the two companies.
The tender offer has not yet commenced; formal terms will be set out in a Schedule TO with an Offer to Purchase, Letter of Transmittal, and related documents, while Selectis will respond on Schedule 14D-9. Selectis shareholders are urged to read these materials carefully when available on the SEC’s website before deciding whether to tender their shares.
The communication contains forward-looking statements about the proposed transaction and its anticipated benefits, subject to risks such as regulatory reviews, the ability to complete the deal, integration challenges, changes in healthcare real estate and long-term care markets, and retention of key personnel.
Selectis Health, Inc. completed the sale of two skilled nursing facilities in Georgia through wholly owned subsidiaries, transferring substantially all related real and personal property. The Sparta and Warrenton facilities were sold for an aggregate purchase price of $13.175 million, subject to customary prorations, holdbacks and adjustments, with $1.3 million placed in escrow that may be released to the sellers if no indemnity claims arise. The company retained rights to collect tenant amounts related to periods before closing. A substantial portion of the net proceeds was used to pay in full a facility mortgage, note obligations, a contractual obligation, transaction costs and other expenses, with the remaining balance expected to support working capital. Concurrently, operations of the facilities were transferred from the prior controlled operators to new operators affiliated with the purchasers, without additional consideration.
Selectis Health, Inc. director Kent J. Lund filed an initial ownership report listing his beneficial holdings of the company’s voting common shares. He reports direct ownership of 15,992 voting common shares and indirect beneficial ownership of 3,261 voting common shares held through his spouse’s IRA. This filing establishes his starting ownership position as of January 1, 2026.